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Abstract
Background: Patients with epilepsy often suffer from other important conditions. The existence of such co-morbidities is
frequently not recognized and their relationship with epilepsy usually remains unexplained.
Methodology/Principal Findings: We describe three patients with common, sporadic, non-syndromic epilepsies in whom
large genomic microdeletions were found during a study of genetic susceptibility to epilepsy. We performed detailed gene-
driven clinical investigations in each patient. Disruption of the function of genes in the deleted regions can explain co-
morbidities in these patients.
Conclusions/Significance: Co-morbidities in patients with epilepsy can be part of a genomic abnormality even in the
absence of (known) congenital malformations or intellectual disabilities. Gene-driven phenotype examination can also
reveal clinically significant unsuspected condition.
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Introduction
Epilepsy is a common neurological condition. Many patients with
epilepsy have additional conditions [1]. When epilepsy is considered
the index condition, co-existing conditions are considered ‘co-
morbidities’. Co-morbidities degrade the quality of life in individuals
with epilepsy [2]. Theoretically, co-morbidities could be causal,
resultant, coincidental or have shared causation, either genetic,
environmental or both. Psychiatric co-morbidities are usually
attributed to seizures, drugs and shared risk factors, such as brain
disease predisposing to both conditions [3]. Somatic co-morbidities
are less well explored. Studying co-morbidity is important to
understand basic pathophysiology and for overall clinical manage-
ment. Treating co-morbidities can reduce the severity of the seizure
disorder [4]. Treatment of seizures can reduce the severity of co-
morbidities. Drugs used to treat one can have effects on the other [5].
Recently, chromosomal microdeletions have been implicated
causing or contributing to some sporadic, ‘common’ epilepsies,
both idiopathic generalized [6–8] and partial [9]. Epilepsy-related
microdeletions often encompass multiple genes, which can
generate contiguous gene syndromes. Due to variable expressivity,
such genomic imbalances may not have an easily recognizable set
of symptoms and signs and may not be suspected during routine
clinical examination. Genetic testing is usually not considered for
patients with sporadic epilepsies in the absence of manifestations
pointing to a syndromic diagnosis.
Here, we present three patients with sporadic epilepsies and
some recognized co-morbidities, who were each found to have a
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quences of the genetic imbalance, we show both that known co-
morbidities can at least partly be explained by the microdeletion
and that important unsuspected co-morbidities can be revealed,
with clinical consequences for patients in both scenarios. Whilst
such phenomena are familiar to many clinical geneticists, they are
much less well-recognised in general to physicians caring for
individuals with epilepsy.
Materials and Methods
The study was approved by the National Hospital for
Neurology and Neurosurgery and Institute of Neurology Joint
Research Ethics Committee. The patients in this manuscript have
given written informed consent (as outlined in the PLoS consent
form) to publication of their case details.
During a multi-centre study of genetic susceptibility to epilepsy
[9], genome-wide typing of single nucleotide polymorphisms had
shown a putatively-pathogenic microdeletion in the three patients
studied here. The patients were selected for investigation from a
pool of ten on the basis of the genes known to be deleted: this was
not intended to be a systematic survey of co-morbidity in patients
with presumptively pathogenic microdeletions. The deletions were
confirmed by array CGH (Nimblegen 135 K v3.1) in all cases, and
for Case 1 also by quantitative PCR (Table 1 and Figure S1). The
deletion regions were annotated in UCSC genome browser
(http://genome.ucsc.edu/).
Detailed phenotypic re-evaluation and clinical investigations
were subsequently undertaken. To assess the potential conse-
quences of each microdeletion, we performed tests based on
information about the function of selected genes in the deleted
region and their known involvement in various diseases other than
epilepsy (see Results for each case and Text S1).
Results
Clinical histories
Case 1. This female patient aged 26 was born at 41 weeks
after an uneventful pregnancy. There was no family history of
seizures. At day 3, she was admitted to special care with vomiting
and a single seizure was recorded. Seizures, described then as
‘asymmetric spasms’, resumed at 6 months and were treated with
antiepileptic drugs. Brain X-ray computerized tomography
showed a left middle cerebral artery territory ischaemic
infarction, considered cryptogenic and to have occurred in the
first week of life. She showed early left hand preference.
Development was normal. At 3.5 years, antiepileptic drugs were
tapered. At age 9, she developed complex partial seizures with
right arm posturing and jerking; drugs were recommenced. Aged
10, startle seizures began, with secondarily generalized tonic-clonic
seizures from age 16. Her seizures were resistant to antiepileptic
drugs. Cognition remained normal.
Neurological examination at 18 years showed right hemiparesis,
with good right hand function, a mild hemiparetic gait and a mild
fixed right ankle deformity. No unusual morphology was noted.
Cranial MRI showed the left medial cerebral artery territory
infarct and left cerebral hemiatrophy. Video-EEG telemetry
recorded left central interictal epileptiform discharges; semiology
pointed to left hemispheric onset, compatible with the MRI lesion.
The medical history was otherwise non-contributory. Seizures
continue despite polytherapy. She was considered to have a
common, sporadic focal epilepsy due to an early cerebral
infarction. A contrast bubble study showed that the heart was
structurally normal with no patent foramen ovale.
Case 2. This female patient aged 44 was born at term as one
of twins. Her twin brother has autism and a sister has epilepsy
attributed to cerebral hypoxia after accidental strangulation.
There was no other family history of epilepsy. She had normal
motor and cognitive development. At 19 years she had a nocturnal
convulsive seizure. At 20, she developed brief complex partial
seizures, starting with a cephalic aura followed by staring and
cessation of activity. At 38 years, she developed left upper eyelid
myokymia, considered incidental at the time. Later progression of
the myokymia to intermittent facial and hand involvement was not
reported by the patient, and only elicited on direct enquiry after
genetic testing.
Neurological examination showed no abnormalities other than
the myokymia. Interictal EEG showed occasional irregular slow
waves over the left temporal area. On hyperventilation, irregular
theta and delta waves appeared over the left temporal and left
frontal areas. Cranial MRI showed decreased volume of the left
hippocampus. Neuropsychometry showed average intellectual
functioning without memory or language impairment. She has
remained completely seizure-free for several years on antiepileptic
drug dual therapy. She was considered to have drug-responsive,
common mesial temporal lobe epilepsy due to hippocampal
sclerosis, with incidental myokymia.
Case 3. This 31 year old male was born at term by normal
delivery after an uneventful pregnancy. There was no family
history of seizures. He walked at 24 months and his parents
considered his development comparable to his siblings. At 30
months, he had an acute neurological illness diagnosed at the time
as viral encephalitis, heralded by generalised tonic-clonic status
epilepticus following an unremarkable upper airway infection. He
suffered in-hospital respiratory arrest, was promptly resuscitated,
and transferred to a regional neurological centre. Cerebrospinal
fluid analysis showed normal protein and glucose, no red cells and
Table 1. Deletion regions and genes in the deleted regions.
Case
Deleted region detected
using Illumina 610quad
microarrays, bp*
Deleted region detected
using Nimblegen 135 K
v3.1microarrays, bp* Genes in the deleted region
Case 1 Chr3:94,994,003–99,339,023 Chr3: 95,069,595–99,333,580 PROS1, ARL13B, STX19, DHFRL1, NSUN3, LOC255025, EPHA6, ARL6, CRYBG3,
MINA, GABRR3, OR5AC2, OR5H1
Case 2 Chr12:4,419,280–5,999,525 Chr12: 4,408,710–5,978,830 AKAP3, C12orf4, DYRK4, FGF6, GALNT8, KCNA1, KCNA5, KCNA6, NDUFA9,
NTF3, RAD51AP1, TMEM16B (ANO2), VWF
Case 3 Chr17:31,922,987–33,333,394 Chr17:31,487,760–33,574,650 ZNHIT3, MYO19, PIGW, GGNBP2, DHRS11, MRM1, LHX1, AATF, ACACA,
C17orf78, TADA2L, DUSP14, AP1GBP1, DDX52, HNF1B, LOC284100
*NCBI build 36, Chr=chromosome.
doi:10.1371/journal.pone.0023182.t001
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3; no organism was isolated. He remained
in focal status epilepticus for more than 48 hours, eventually
controlled on phenobarbitone and phenytoin. He had a transient
left hemiparesis. Antiepileptic drugs were tapered over three
months. He remained seizure-free for seven years, but was noted
to have learning difficulties. Health was otherwise excellent.
Habitual seizures started at 10 years. Seizures were never
controlled despite several antiepileptic drug regimes. Seizures,
occurring 2–3/week, started with a brief autonomic aura,
progressing to unresponsiveness, with staring and oro-manual
automatisms. Cranial MRI showed right hippocampal sclerosis
(Figure S2). On EEG-videotelemetry, four habitual partial seizures
were recorded; lateralising semiological signs included nose
rubbing with his right hand and post-ictal urinary urge; ictal
EEG showed bitemporal rhythmic theta discharge, more prom-
inent and sustained on the right, with right temporal interictal
epileptiform discharges. Neuropsychometry showed mild learning
disability, globally weak memory, but low risk of global amnesia in
the context of left temporal structural normality. At 28, he had a
right anterior temporal lobectomy. He has been free of seizures to
the more recent follow-up at 36 months, with tapering of
antiepileptic drugs. Repeat neuropsychometric assessment showed
improvement of attention span, verbal memory and spatial
reasoning skills; his visual memory and higher-level visual
processing skills had slightly declined. Histopathology of the
lobectomy specimen confirmed hippocampal sclerosis, without
mossy fibre sprouting (Figure S2). He was considered to have
surgically-remediable, typical sporadic mesial temporal lobe
epilepsy due to hippocampal sclerosis. The medical history was
otherwise unremarkable.
Gene-Driven Clinical Investigations
Case 1 (del 3q11.2). The microdeletion included PROS1
(Table 1), which encodes protein S, a vitamin K-dependent plasma
protein co-factor for the anticoagulant protease activated protein
C, that itself inhibits activated factors V and VIII. PROS1
mutations and deletions cause autosomal dominant hereditary
thrombophilia [10]. Given the unexplained early cerebral
infarction, we suspected protein S functional deficiency, since
thrombophilia is a stroke risk factor in neonates and children [11].
Case 1 had free and functional protein S deficiency (respectively
0.31 IU/ml, normal range 0.50–1.34; 0.28 IU/ml, normal range
0.50–1.20), confirmed on repeat testing four months later. She was
heterozygous for the C677T MTHFR polymorphism, with normal
total serum homocysteine. The remainder of the thrombophilia
screen, including antiphospholipid antibodies, which may induce
acquired protein S deficiency, yielded normal results.
Management consequences resulting from these findings
comprised advice on risk reduction measures against thrombosis,
including maintenance of hydration, avoidance of oestrogen-
containing hormonal contraception, and low molecular-weight
heparin thromboprophylaxis in situations with increased
thrombotic risk. Long-term prophylactic anticoagulation was not
indicated.
On directed questioning after these findings, a family history of
thrombophilia emerged. Her maternal grandfather had had three
known pulmonary emboli, from the age of 30 years, and had been
anticoagulated until death at 56. Both aCGH and quantitative
PCR analysis revealed that her mother also had the same PROS1
deletion (Figure S1 for quantitative PCR results). She has low free
protein S (0.39 IU/ml) and normal functional protein S (0.59 IU/
ml), is healthy and has never had thrombotic events or pregnancy
losses. Such variable expressivity of PROS1 deletions is well known
[10].
Dense surface modelling analysis of the patient’s face did not
uncover facial dysmorphism (Figure S4, Video S1).
Case 2 (del 12p13.32-p13.31). The microdeletion included
KCNA1, KCNA5 and VWF genes (Table 1).KCNA1 encodes a
voltage-gated delayed potassium channel (Kv1.1). KCNA1
mutations cause episodic ataxia type 1 with myokymia (EA1).
Nerve excitability testing in the patient showed several
abnormalities (Figure 1) which are also observed in patients with
EA1 [12]. However, the patient was on carbamazepine at the time
of testing and therefore blockade of voltage-gated sodium channels
may have contributed to some of the observed changes, which
may not be solely due to reduced Kv1.1 function. During needle
electromyography the patient did not have fine involuntary finger
movements and testing showed normal motor unit discharges
despite obvious myokymia during other observations.
KCNA5 encodes a voltage-gated potassium channel (Kv1.5)
expressed in human atria. KCNA5 loss-of-function mutations cause
atrial fibrillation [13]. Case 2 had had unprovoked, brief,
paroxysmal episodes of fast palpitations, without other symptoms.
On directed questioning, it emerged that her father (deceased) had
had paroxysmal atrial fibrillation from his forties, and had been on
treatment. The patient’s resting electrocardiogram and 24-hour
ambulatory electrocardiogram, both performed when she was
asymptomatic, were normal. Further ECG monitoring is planned.
VWF encodes von Willebrand factor (vWF) glycoprotein that
binds platelets via glycoprotein 1b/IX to subendothelial collagen
and carries factor VIII. vWF is crucial to haemostasis. VWF
mutations cause von Willebrand disease, but incomplete pene-
trance is known [14]. Factor VIII (1.4 IU/ml, normal range 0.5–
2.0), vWF antigen (1.24 IU/ml, normal range 0.5–1.6) and
ristocetin cofactor (1.04 IU/ml, normal range 0.5–2.0) levels were
all normal.
Dense surface modelling analysis of the patient’s face did not
uncover facial dysmorphism (Figure S4, Video S2).
Case 3(del 17q12). The deletion encompasses ACACA and
HNF1B (Table 1). HNF1B mutations and deletions cause renal cyst
and diabetes syndrome [15] and hypomagnesemia [16]. The
subject’s oral glucose tolerance test (OGTT) showed a normal
glucose profile, but in keeping with the HNF1B deletion, the
dynamic insulin response was impaired: at 60 minutes, with peak
glucose concentration, his insulin level was .8 standard deviations
below the published mean (Figure S3 for dynamic profiles of
glucose, insulin, and other metabolites). His HbA1c level,
representing an integrated measure of glycemic control over the
preceding 120 days, was 5.9%, at the upper limit of the normal
range (4.0–6.0%). Serum magnesium was low (0.54 mmol/L,
normal range 0.6–1.0 mmol/L). Renal ultrasound showed
bilateral cysts (not shown). Estimated glomerular filtration rate
was low (84 mL/min/1.73 m
2), indicating mildly reduced kidney
function (chronic kidney disease stage 2, www.renal.org/
CKDguide/ckd.html). These findings fit with the known
consequences of HNF1B deletion, but none were suspected or
detected before discovery of the microdeletion.
The metabolic profile for this patient is complex. ACACA
encodes acetyl co-A carboxylase 1 (ACC1), the key enzyme in
hepatic fatty acid synthesis [17]. We hypothesized that the ACACA
deletion might cause lower levels of ACC1, altering fatty acid
metabolism. Fasting total triglyceride levels were low (0.4 mmol/
L, normal range 0.4–2.3 mmol/L). Acetyl-CoA carboxylation to
malonyl-CoA cannot directly be measured in blood. However, its
impairment could elevate citrate levels. Citrate is normally
undetectable in urine. His fasting urine had no detectable citrate,
but a sample after OGTT showed citraturia, compatible with
hypercitratemia (not measured). This suggests impaired citrate
Epilepsy Co-Morbidity and Microdeletions
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conversion, which may be overwhelmed by mass action from
excess citrate production, as well as being impaired by a lack of
insulin activation. The alternative interpretation of an increased
flux through the citrate synthetic (tricarboxylic acid cycle) pathway
is unlikely, because his mitochondrial beta-oxidation is normal at
rest and normally-suppressed through the OGTT (as reflected by
dynamic total and fractional acyl-carnitine levels, Figure S3).
These observations are consistent with deficient ACC1 activity
and with lack of dynamic activation of ACC1 in the context of an
impaired insulin response. The absence of crotonyl derivatives on
gas chromatography mass spectroscopy (data not shown) excludes
a generalised functional biotin co-enzyme deficiency, which might
have been an alternative explanation.
Consistent with disordered fat metabolism, his body build was
lean (body mass index (BMI) 17.5 kg/m
2,2
nd centile WHO-CDC
scale). Re-inspection of his cranial MRI showed attenuation of
subcutaneous fat deposits (Figure 2). ACACA and ACLY (the gene
encoding ATP-citrate lyase) are both known to be involved in
lipogenesis in human adipose tissue and are regulated in a complex
fashion by body energetics [18], though we have not uncovered
the precise mechanism in our patient. We note also that in a
Figure 1. Nerve excitability profile of Case 2. In the nerve excitability profile, there was an abnormally enhanced late subexcitability of the
recovery cycle (A) and a pronounced S2 accommodation and reduced TEd (90–100 ms) value at the end of the depolarising threshold electrotonus
(upper trace in B). C,D: scatter plots of these nerve excitability parameters in the patient (filled circle) and 16 normal controls (open symbols). Dashed
lines (A–D) show 95% confidence interval of the normal range. See Text S1 for detailed description of methods.
doi:10.1371/journal.pone.0023182.g001
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deletion [16], wide variation of BMI was observed (2nd–100th
centile, median 67th centile), suggesting overall that variable
expressivity and other factors contribute to BMI, which is a blunt
phenotype. His serum levels of fat-soluble vitamins A and E were
normal. His low serum vitamin D level is difficult to interpret,
possibly attributable to chronic therapy with enzyme-inducing
antiepileptic drugs.
Other predicted complex downstream consequences of deficient
ACC1 function include ubiquinone deficiency, found to be present
in the patient (33 pmol/mg; normal range 37–133 [19]). Ubiqui-
none deficiency is a cause of cerebellar ataxia, cerebellar atrophy
or hypoplasia [20]. The patient’s father noted that the patient had
always lacked dexterity and agility, being able as a child, for
example, to run a sprint but not hurdles. His cranial MRI aged 28
showed mild cerebellar atrophy (Figure 3). These findings are all in
keeping with functional deficiency in ACC1, although an
additional contribution from LHX1 deficiency cannot be excluded
for the cerebellar phenotype [21]. Deficits in coordination and
motor skills in patients with chromosome 17q12 deletion have
been reported recently [22].
The LHX1 gene, also residing in the deleted region, is a
homeobox gene expressed in the developing brain and involved in
neuronal differentiation [23] and cortical lamination [24]. In
mouse models, the Lhx1 gene is required for regulating the
vertebrate head organizer [25]. Therefore, LHX1 emerges as a
plausible candidate responsible for the neurological phenotypes in
patients with chromosome 17q12 deletion [22], possibly affecting
brain development. Review of the tissue resected at temporal
lobectomy of Case 3 showed a few cells deep in the temporal lobe
white matter that contained abnormal storage material, that was
PAS-positive, suggestive of excessive glycosylation (Figure 4). The
nature of the material could not be further clarified. No such
changes have been noted in over 200 other temporal lobectomy
specimens resected from patients with drug-resistant mesial
temporal lobe epilepsy [26]. However, cortical lamination, which
we considered might have been affected by LHX1 deficiency, was
normal when examined with several cortical layer markers
(Figure 5). Neither have we detected any retinal abnormalities
(Text S1).
Clinical genetic examination after discovery of the microdele-
tion showed subtle evidence of dysmorphism, not articulated by
several neurologists during pre-surgical evaluation: he had a
narrow face, mildly receding forehead, little facial subcutaneous
fat, prominent nasal bridge, broad nasal base, long and wide
philtrum and large mouth. His shoulders were narrow, and he had
pectus excavatum, limited elbow extension, flat hands, prominent
finger joints, mild cutaneous 2–3 finger syndactyly, clinodactyly of
the 5th fingers, under-developed hypothenar regions and narrow
feet. Facial dysmorphism was confirmed by quantitative analysis in
comparison with 200 age-, sex- and ethnicity-matched controls
(Figure 6, Video S3). It should be emphasised that on first
examination at our centre, facial abnormalities were not identified,
and these were only documented by formal clinical genetics review
Figure 2. Attenuation of subcutaneous fat in Case 3. (A) Coronal
T2-weighted image showing the patient has attenuation of scalp
subcutaneous fat (arrows). (B) Normal appearance in a patient with
epilepsy without 17q12 deletion (arrows). Subcutaneous scalp fat was
present on cranial MRI in 150 patients with temporal lobe epilepsy who
did not carry this deletion.
doi:10.1371/journal.pone.0023182.g002
Figure 3. Cerebellar atrophy in Case 3. T1-weighted MRI reveals
cerebellar atrophy. Note this is a T1-weighted image (not a T2-weighted
image as in Figure 2A); the bright layer in the scalp is diploe, not
subcutaneous fat.
doi:10.1371/journal.pone.0023182.g003
Figure 4. Neuropathology of resection specimen from Case 3.
In the deep white (periventricular region) of the temporal lobectomy
specimen of Case 3, a single cluster of globoid cells with granular
cytoplasm was present. The cells showed PAS positivity, which could
indicate glycogen storage, but the cells did not contain myelin debris
and there was no evidence of demyelination. The cells were only
present focally. Further investigation regarding histogenesis of these
cells and characterization of cytoplasmic contents was not possible.
Similar cell types were not noted in the hippocampus.
doi:10.1371/journal.pone.0023182.g004
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microdeletion.
These manifestations are not described in most other published
cases with overlapping 17q12 deletions, including 14 patients with
autism, schizophrenia or seizures [22,27,28]. However, several
facial photographs of cases in the report by Moreno-De-Luca et al.,
2010 [22], especially case 1, show overlapping facial features.
These include a narrow face, broad nasal base and large mouth.
This comparison indicates the difficulties in describing the human
face and the importance of having faces evaluated by specialist
dysmorphologists, or through the use of objective techniques such
as dense surface modelling.
None of the findings above were associated with any symptoms
volunteered by the patient, nor revealed during any investigations
prior to specific phenotypic re-evaluation after discovery of the
microdeletion. Some of the findings have direct clinical conse-
quences for the patient: he has been started on magnesium and
ubiquinone supplements and will undergo regular monitoring of
renal function and glucose levels.
Discussion
We describe three patients with epilepsy, in whom co-
morbidities are explicable by the same microdeletion that is
putatively related to each individual’s epilepsy itself, consistent
with the genomic disease model. Notably, the microdeletions were
identified in adults who were considered before the study to have
non-syndromic epilepsies associated with underlying cerebral
abnormalities (cerebral infarction, hippocampal sclerosis). None
were known to have congenital anomalies or intellectual
disabilities. Extended phenotypes were sought only after discovery
of microdeletions. Previously, the co-morbidities had either been
considered unrelated to the epilepsy (e.g. myokymia) or not
suspected at all (e.g. thrombophilia, metabolic derangement and
kidney dysfunction). In all three patients, the findings had clinical
consequences for counselling, further clinical investigation or
monitoring, and additional treatment regarding the co-morbidity.
We emphasise this study is not a systematic survey. We selected
3/10 patients from one centre from our original multi-centre study
[9] on the basis that their microdeletions contained genes that
might cause explorable co-morbidities, in order to illustrate the
concept of epilepsy as one manifestation of a genomic condition. A
systematic search for underlying genetic causes of epilepsies with
co-morbidities would seem warranted.
The individual details are of interest. In Case 1, we postulate
that PROS1 deletion-related thrombophilia predisposed to cerebral
infarction, the location of which was compatible with causation of
the patient’s epilepsy. In Case 2, myokymia was initially
considered to be unrelated to the epilepsy, but both might be
explained by deletion of KCNA1. Effects of KCNA1 mutations, at
least in some cases, are attributable to a dominant-negative
mechanism [29]; the mechanism in Case 2, with a microdeletion,
is not yet known. In Case 3, ACACA deletion is associated with
disordered endogenous fatty acid metabolism. This may cause the
attenuated subcutaneous fat seen in our patient. Loss of one copy
of the gene seems to have modest effect on the overall health of the
patient. It is possible that the infantile ‘encephalitic’ illness
represented ACC1 deficiency-related metabolic crisis, causing
Figure 5. Cortical lamination in Case 3. Examination with several
cortical layer markers (antibodies against proteins denoted in each
panel) revealed normal cortical lamination in Case 3.
doi:10.1371/journal.pone.0023182.g005
Figure 6. Facial dysmorphism in Case 3. (A) Dense surface
morphology (DSM) results (See Text S1 for details). The scatter plot
shows age (horizontally) against DSM distance (vertically) between the
matched mean face and the patient and 200 control faces. Distance
from the patient-matched mean face was linearly regressed against age
for all controls. The patient was fitted to the appropriate regression and
a 95% confidence interval was calculated for the predicted distance
from the patient-matched mean. The scatter plot shows that Case 3
(square) is well outside the 95% confidence interval (bar). (B) Heat maps
using a red–green-blue spectrum to depict inward–null-outward
displacement along the surface normal for the patient face relative to
its matched mean face using 50 control subjects. Displacement is
expressed as the number of standard deviations (Stdv) from the mean.
The lateral patches of red and yellow reflect an unusually narrow face.
The red and yellow cheek patches and the null displaced green islands
in the gonial region of the lower jaw reflect diminished fatty tissue
rather than reduced gonial/skeletal width. Some fullness of the perioral
region is shown (blue).
doi:10.1371/journal.pone.0023182.g006
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acetyl-coenzyme A carboxylases ACC1 and ACC2 is being
proposed as a treatment for obesity [30], but this case’s
information may indicate it not be a harmless option, at least in
childhood.
Determining the pathogenicity of a given microdeletion presents
a challenge shared across diseases: several methods have been
suggested [31], but none is necessarily absolute in itself.
Establishing functional consequences as described here is one
method of determining clinical significance; the microdeletions in
this report are clinically significant for at least the co-morbidities in
these patients. In our original report, microdeletions .1M bi n
size were significantly associated with epilepsy. None of the
microdeletions reported here were found in 1299 controls [9];
therefore apart from the speculative mechanisms explaining co-
morbidities considered above, these microdeletions might also
contain other candidate genes for epilepsy. Although in Case 1,
and likely in Case 2, the microdeletion was inherited from a parent
without known epilepsy, the microdeletion may still be a risk factor
for the epilepsy in the proband: microdeletions with variable
phenotypic expressivity are commonly inherited from unaffected
parents, as shown both in epilepsy [7] and other neuropsychiatric
conditions [32]. Many smaller microdeletions have been similarly
implicated in a variety of epilepsies [33].
With the increased use of genomic microarrays both in research
studies and clinical practice, more and more clinically relevant copy
number variants are being detected. Broadly, they fall into two
classes – (i) highly penetrant with clear, recurrent clinical
associations and (ii) those with variable expressivity found in
individuals with a broad range of phenotypes [32,34]. The
mechanism of action of most of these copy number variants is
unknown. Our results suggest that clinical investigations based on
the knowledge of genes in the region of a copy number variant may
provide insights into the mechanism of disruption caused by that
copy number variant. For rare or private (i.e. non-recurrent) copy
number changes, clinical testing driven by genetic hints, as in our
Case 1 with loss of PROS1, can be informative and might confirm
that a given microdeletion is functionally important, and establish a
likely genotype-phenotype association. Moreover, such gene-driven
investigations may reveal novel, unappreciated phenotype correla-
tionseveninalreadywell-described syndromeswith well-established
clinical consequences, as shown here for the 17q12 microdeletion.
It should be noted that we had no reason to study these genes in
these patients a priori, because (a) the originally-documented
epilepsy phenotypes of the patients were not unusual for their
respective ‘common’ epilepsies, (b) there were no obvious
indications for cytogenetic testing (before assessment by a clinical
geneticist): co-morbidities were present but there was neither
intellectual disability nor obvious congenital anomalies; and (c)
there was no specific clue in the phenotype for a particular locus.
Detecting significant microdeletions can thus provide additional
insights to human biology at an individual level. This concept itself
is not novel, being well-appreciated by clinical geneticists, and
reported in obviously syndromic epilepsies, but the present
findings suggest that the concept also applies to apparently non-
syndromic, sporadic epilepsies – which make up the vast majority
of cases of epilepsy. Non-syndromic epilepsies can thus be part of
unsuspected complex conditions. The converse is likely to apply as
well: some patients with, for example, thrombophilia, may be
known to have epilepsy as a co-morbidity, and this may in fact
represent an unsuspected genomic abnormality. Wider apprecia-
tion of genomic abnormalities linking co-morbidities may bring
clinical specialties back to closer daily interaction, especially as it is
known that specialists often overlook co-morbidities [35,36].
With the personal genome ‘on request’ on the horizon through
next generation sequencing, detailed phenotyping and clinical
investigations will be a critical complement and allow interpreta-
tion of genomic findings, dissection of the core phenotype, and
promotion of health and disease prevention [37]. There are
intricacies and ethical issues to be surmounted [38], and in each
case the work will be time-consuming, but there are also significant
potential benefits for clinical practice and science, and especially
for improved and comprehensive health care for individual
patients.
Supporting Information
Figure S1 PROS1 copy number analysis by quantitative
PCR. Results of PROS1 copy number analysis by quantitative
PCR analysis. RQ -relative quantity.
(TIF)
Figure S2 Hippocampal sclerosis in Case 3. (A) T1-
weighted magnetic resonance imaging of the Case 3 revealed right
hippocampal volume loss (arrow) compatible with hippocampal
sclerosis. (B) Histopathology of the lobectomy specimen from Case
3 confirmed hippocampal sclerosis, without mossy fibre sprouting.
There was neuronal loss in CA1, CA4 and gliosis on GFAP. The
section shown is immunolabelled for NeuN.
(TIF)
Figure S3 Dynamic profiles of glucose, insulin, and
other carnitine esters. Dynamic profiles of glucose, insulin,
and other carnitine esters. NEFA - non-esterified fatty acids.NEFA
- non-esterified fatty acids.
(TIF)
Figure S4 Dense surface morphology (DSM) results for
Case 1 and Case 2. (A) The scatter plot shows age (horizontally)
against DSM distance (vertically) between the matched mean face
and the patient and 200 control faces. Distance from the patient-
matched mean face was linearly regressed against age for all
controls. The patient was fitted to the appropriate regression and a
95% confidence interval was calculated for the predicted distance
from the patient-matched mean. The two scatter plots show that
Case 1 is just within the 95% confidence interval; Case 2 is close to
the predicted value. (B, C) Heat maps using a red–green-blue
spectrum to depict inward–null-outward displacement respectively
along the surface normal of the case face relative to its matched
mean face (of 50 control subjects). Displacement is expressed as the
number of standard deviations from the mean. (B) For Case 1, the
long and full nose is indicated by blue patches; the opposing blue-
yellow patches on the alae reflect a rightward deflection of the
nose. Cyan patches on the cheeks emphasise a broad zygomatic
arch. Red on the forehead and periorbital regions indicate a
backward slope and deeper set eyes respectively. The mild
recession of the mandible results in a red chin. (C) For Case 2,
yellow under the chin and cyan patches on the cheeks reflect a
slightly shorter and squarer face than the matched mean. Some
flattening of the supraorbital regions is shown red. A small degree
of flattening of the nasal bridge is also shown (red).
(TIF)
Text S1 Supplementary methods and results.
(DOC)
Video S1 Animations of face morphs. Animations of face
morphs offer the best visualisation of face shape differences when
comparing each case and its age/sex-matched mean face. The
unusual narrowness of Case 3’s face is dysmorphic. S1 - Case 1.
(WMV)
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PLoS ONE | www.plosone.org 7 August 2011 | Volume 6 | Issue 8 | e23182Video S2 Animations of face morphs. Animations of face
morphs offer the best visualisation of face shape differences when
comparing each case and its age/sex-matched mean face. The
unusual narrowness of Case 3’s face is dysmorphic. S2 - Case 2.
(WMV)
Video S3 Animations of face morphs. Animations of face
morphs offer the best visualisation of face shape differences when
comparing each case and its age/sex-matched mean face. The
unusual narrowness of Case 3’s face is dysmorphic. S3 - Case3.
(WMV)
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